IDEAYA Biosciences, Inc. (IDYA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $34.26
- As of
Kresmion compiles this page from IDYA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
IDEAYA Biosciences, Inc. (IDYA): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-04.
See the full IDYA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for IDYA on one page. Preview it with sample data, then open it live with a free account.
Preview the IDYA dossierActive signals for IDYA
- highCONSENSUS_SELL
4 tracked funds reduced IDYA this 2026Q2, institutional consensus
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 9.5%, EPS $-1.22 vs $-1.1142 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +104% to IDYA (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1490% to IDYA (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 92% of IDYA (2026Q2)
FREE, NO ACCOUNT
Every signal on IDYA, as it fires
You are seeing 5 of 13 signals recorded on IDYA since 2026-05-24.
The five above landed across 3 days. The other 8 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in IDYA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 45166A102 · 2026Q2 | $11.2M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 45166A102 · 2026Q2 | $1.5M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 45166A102 · 2026Q2 | $774K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 45166A102 · 2026Q2 | $391K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, IDYA
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
IDYA against its peers
IDYA's operating margin of -72.8% ranks in the 56th percentile of 16 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | IDYA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 219M USD | 47.7M USD | 61 | 18 |
| Operating margin | -72.8% | -226.5% | 56 | 16 |
| Net margin | -52.0% | -110.0% | 56 | 16 |
| Return on equity | -11.1% | -29.7% | 70 | 24 |
| 1 year | 28.0% | 26.5% | 53 | 19 |
Peers (24): XENE, ACAD, GRTX, LEGN, VKTX, ARQT, VCYT, CELC, TLX, CPRX, DNLI, DYN, RLAY, RCUS, TNGX, ELVN, EWTX, ZLAB, PGEN, ATAI, DNTH, BEAM, MBX, NAMS. Left out: PBLS (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (IDYA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow IDYA on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to IDYA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.